Paliperidon Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Teva, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is used to manage symptoms of schizophrenia in adults and adolescents. GNH USA supplies Paliperidon Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidon Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for the treatment of schizophrenia and related psychotic disorders.

- Schizophrenia: Reduces the frequency and severity of psychotic episodes and helps maintain long‑term stability. - Schizoaffective disorder: Controls mood‑related symptoms while addressing core psychotic features. - Maintenance therapy after acute stabilization: Provides sustained drug exposure to prevent relapse without daily oral dosing.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain or erythema. - Headache. - Weight gain. - Restlessness or akathisia. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe orthostatic hypotension. - Seizures. - Hyperglycaemia or new‑onset diabetes. - Elevated prolactin with associated endocrine effects.

When prescribing Paliperidone palmitate, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: Check weight, glucose and lipid profiles regularly. - Pregnancy and lactation: Use only if the potential benefit outweighs risk. - Elderly patients: Start at the lowest recommended dose and monitor closely for sedation and falls. - Drug‑interaction review: Assess concomitant medications that may affect cardiac or metabolic status. - Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with other medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase paliperidone exposure and risk of toxicity. - CNS depressants (e.g., benzodiazepines, opioids): May enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: May potentiate orthostatic hypotension. - Antidiabetic agents: May require dose adjustment due to altered glucose control. - Anticholinergic drugs: May increase risk of constipation and urinary retention. - QT‑prolonging agents: May modestly increase QT interval when combined.